228 related articles for article (PubMed ID: 9778690)
1. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.
McGuire JJ; Russell CA
Oncol Res; 1998; 10(4):193-200. PubMed ID: 9778690
[TBL] [Abstract][Full Text] [Related]
2. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
3. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
4. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.
McGuire JJ; Haile WH; Russell CA; Galvin JM; Shane B
Oncol Res; 1995; 7(10-11):535-43. PubMed ID: 8866666
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
[TBL] [Abstract][Full Text] [Related]
6. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
7. Preferential selection during therapy in vivo by edatrexate compared to methotrexate of resistant L1210 cell variants with decreased folylpolyglutamate synthetase activity.
Rumberger BG; Schmid FA; Otter GM; Sirotnak FM
Cancer Commun; 1990; 2(9):305-10. PubMed ID: 2206778
[TBL] [Abstract][Full Text] [Related]
8. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
9. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for decreased folylpoly-gamma-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line.
Leclerc GJ; York TA; Hsieh-Kinser T; Barredo JC
Leuk Res; 2007 Mar; 31(3):293-9. PubMed ID: 16884772
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients.
Lenz HJ; Danenberg K; Schnieders B; Goeker E; Peters GJ; Garrow T; Shane B; Bertino JR; Danenberg PV
Oncol Res; 1994; 6(7):329-35. PubMed ID: 7865908
[TBL] [Abstract][Full Text] [Related]
13. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
14. DL-beta,beta-difluoroglutamic acid mediates position-dependent enhancement or termination of pteroylpoly(gamma-glutamate) synthesis catalyzed by folylpolyglutamate synthetase.
McGuire JJ; Hart BP; Haile WH; Rhee MS; Galivan J; Coward JK
Arch Biochem Biophys; 1995 Aug; 321(2):319-28. PubMed ID: 7646057
[TBL] [Abstract][Full Text] [Related]
15. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
16. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines.
McCloskey DE; McGuire JJ; Russell CA; Rowan BG; Bertino JR; Pizzorno G; Mini E
J Biol Chem; 1991 Apr; 266(10):6181-7. PubMed ID: 2007575
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of human folylpolyglutamate synthetase by suramin.
McGuire JJ; Haile WH
Arch Biochem Biophys; 1996 Nov; 335(1):139-44. PubMed ID: 8914844
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
Mini E; Moroson BA; Franco CT; Bertino JR
Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
[TBL] [Abstract][Full Text] [Related]
19. Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H
Anticancer Drugs; 1999 Aug; 10(7):677-83. PubMed ID: 10507318
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
